Camden Partners Nexus co-leads $3.7M investment in pharmaceutical company treating hearing loss - Technical.ly Baltimore

Business

Dec. 12, 2018 2:12 pm

Camden Partners Nexus co-leads $3.7M investment in pharmaceutical company treating hearing loss

The funding from the Baltimore-based venture fund and Savoir Capital is part of a Series A round for Spiral Therapeutics, which has an R&D presence at Johns Hopkins.
Lab space at Johns Hopkins’ FastForward 1812.

Lab space at Johns Hopkins' FastForward 1812.

(Photo by Stephen Babcock)

Early-stage pharmaceutical company Spiral Therapeutics received $3.7 million in new investment as it looks to advance treatments for hearing loss and other inner ear disorders.

The first close of the Series A round was led by Baltimore-based Camden Partners Nexus and Savoir Capital.

The company’s initial drug candidate, LPT99, moved into the clinical phase of a Phase I study this month. In the fall, the company reported positive feedback from the U.S. Food and Drug Administration in response to an initial submission, which plans to develop the treatment for the prevention of chemotherapy-induced hearing loss in pediatric patients. The company is also exploring further use for other types of hearing loss.

“This round of financing allows us to take LPT99 into the clinic and further validates our development strategy,” said Hugo Peris, founder and CEO of Spiral Therapeutics.

Launched in early 2016, the San Francisco–based company has a research and development presence in Baltimore through a collaboration with Johns Hopkins, as well as in Barcelona, Spain.

“Spiral Therapeutics brings together innovative therapies addressing inner ear disorders and a seasoned and energetic management team,” George Petrocheilos, a general partner at Camden Partners who will join the company’s board, said in a statement. “Its solid R&D foundation and the meaningful collaborations with leading medical institutions like Johns Hopkins and UCSF make Spiral an ideal investment for Camden.”

Camden Partners Nexus, the biomedical-focused venture fund of Inner Harbor–based Camden Partners that focuses on companies commercializing research, recently made investments in local startups including Sisu Global Health and WindMIL Therapeutics, among other deals since making its final close at the end of 2017.

Advertisement

Companies: Camden Partners
-30-
BECOME A CONTRIBUTOR TO THE JOURNALISM FUND TO COMMENT
Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

University of Maryland awarded $200M for flu vaccine research

Early Charm Ventures launches Abri Science with $225K in funding

Intelehealth launches crowdfunding campaign to expand primary care access around the world

SPONSORED

Baltimore

Why two eminent Baltimore higher-ed institutions collaborated to create this unique dual degree program

Annapolis Junction, MD

Asymmetrik

FULL-STACK DEVELOPER

Apply Now

Annapolis Junction, MD

Asymmetrik

SOFTWARE ENGINEER

Apply Now

Annapolis Junction, MD

Asymmetrik

FRONT-END DEVELOPER

Apply Now

Meet the Aerium: An algae air purifier created by IMET PhD candidates

AgeneBio receives $3.4M for development of Alzheimer’s treatment

5 questions with Jason Becker: Leading product development through an equity lens at Allovue

SPONSORED

Baltimore

What Asymmetrik is doing to help lead healthcare’s digital transformation

Baltimore

Protenus

DevOps Engineer

Apply Now

Philadelphia

Vistar Media

Sr. Software Engineer

Apply Now

Philadelphia

Vistar Media

Front End Engineer

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!